{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intra-arterial+Mannitol",
    "query": {
      "intervention": "Intra-arterial Mannitol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T14:38:58.083Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02800486",
      "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligoastrocytoma",
        "Glioma",
        "Brain Neoplasm",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Tumor, Recurrent",
        "Brain Neoplasm, Malignant"
      ],
      "interventions": [
        {
          "name": "Intra-arterial Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Intra-arterial Mannitol",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated re-irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-05",
      "completion_date": "2036-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02800486"
    },
    {
      "nct_id": "NCT01180816",
      "title": "Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Super-Selective Intraarterial Intracranial Infusion of Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2010-08",
      "completion_date": "2020-08-11",
      "has_results": false,
      "last_update_posted_date": "2021-03-04",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180816"
    },
    {
      "nct_id": "NCT01386710",
      "title": "Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab and Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2011-09",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01386710"
    },
    {
      "nct_id": "NCT02861898",
      "title": "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Brain Cancer",
        "Brain Neoplasm",
        "Brain Tumor",
        "Brain Neoplasm, Malignant",
        "EGFR Gene Overexpression",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Intra-arterial Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Intra-arterial Mannitol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02861898"
    },
    {
      "nct_id": "NCT01238237",
      "title": "Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme (GBM)",
        "ANAPLASTIC ASTROCYTOMA (AOA)",
        "GBM",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Superselective Intraarterial Cerebral Infusion of Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-12",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01238237"
    },
    {
      "nct_id": "NCT00983398",
      "title": "Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Embryonal Neoplasm",
        "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered",
        "Germ Cell Tumor",
        "Medulloblastoma",
        "Medulloepithelioma",
        "Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Central Nervous System Embryonal Neoplasm",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Medulloblastoma",
        "Recurrent Primitive Neuroectodermal Tumor"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Mannitol",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sodium Thiosulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2009-07-09",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Portland, Oregon",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983398"
    },
    {
      "nct_id": "NCT01269853",
      "title": "Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-10",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269853"
    },
    {
      "nct_id": "NCT00968240",
      "title": "Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-04-22",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968240"
    },
    {
      "nct_id": "NCT02819479",
      "title": "Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Radiation Necrosis"
      ],
      "interventions": [
        {
          "name": "25% Mannitol",
          "type": "DRUG"
        },
        {
          "name": "Low-dose Intra-arterial Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Norton Healthcare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-11-23",
      "completion_date": "2019-06-06",
      "has_results": true,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-09-17T14:38:58.083Z",
      "location_count": 2,
      "location_summary": "Lexington, Kentucky • Louisville, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819479"
    }
  ]
}